Forward P/S Multiple: GlucoTrack (GCTK)

GlucoTrack, Inc. (GCTK) management aims to launch innovative non-invasive glucose monitoring as it navigates the certification process. The projected P/S dynamics in the daily price action on the GURU.Markets chart reflect that the metric has reached the level. Demand for such gadgets remains stable and is not subject to seasonality. The expected conclusion of implantable system tests will serve as a key driver, while the biotech's financial risks are already priced in by the market.

glucotrack.com - GCTK Market Cap to Projected Revenue (period 07/04/2022 - 11/13/2026)

Summary analytical data breakdowns for glucotrack.com (GCTK)

- market price and analyst price targets:

Price Chart GlucoTrack, Inc.|GCTK - Consensus Target

- company stock exchange capitalization indicators:

Market Capitalization GlucoTrack, Inc.|GCTK - Total Enterprise Value

- issuer book value statistics:

Book Value per Share GlucoTrack|GCTK - Accounting Capitalization|Market Capitalization to Book Value Ratio glucotrack.com|GCTK - Company Total Asset Base

- debt and liquidity data:

- financial results and valuation multiples details:

GCTK - Company Net Income|Expected Profit GlucoTrack, Inc.|GCTK - Market Cap to Net Income Ratio|Projected Price to Earnings GlucoTrack, Inc.|GCTK - PEG Multiple|EV/EBITDA Multiple GlucoTrack, Inc.|GCTK - Operating income before deduction of amortization|Earnings per share for the last twelve months GlucoTrack|GCTK - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months glucotrack.com|GCTK - Net earnings per share growth this year|Earnings growth forecast for next year GlucoTrack, Inc.

- sales and revenue indicators:

GCTK - Company Total Revenue|Company Projected Revenue GlucoTrack|GCTK - Market Cap to Revenue Ratio|Forward Price-to-Revenue Multiple GlucoTrack, Inc.

Fundamental company analysis:GCTK (GlucoTrack, Inc.)

Forward P/S determines investment attractiveness by comparing current market capitalization with expected revenue to identify whether an asset is overvalued or possesses growth potential. By analyzing the projected P/S of the business on GURU.Markets, an investor can see the market consensus regarding the non-invasive technologies of GlucoTrack, Inc. (GCTK), whose pricing power and inelastic demand for glucose monitoring ensure the fundamental stability of cash flows.

Who GlucoTrack, Inc. competes with

Price-to-Projected Revenue Ratio Dexcom DXCM|PEN - Forward Price-to-Revenue Multiple|Novanta Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Haemonetics Company|INSP: Forward P/S Multiple|Market Cap to Projected Revenue PRCT|CNMD (CONMED) - Forward P/S Multiple|Pulse Biosciences Inc (PLSE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple INMD|Forward Price-to-Revenue Multiple Picard Group PMI|Forward P/S Multiple SRDX (Surmodics, Inc.)|Forward P/S Multiple senseonics.com SENS|NPCE - Price-to-Projected Revenue Ratio|TCMD: Price-to-Projected Revenue Ratio|SNWV (SANUWAVE Health, Inc.) - Forward Price-to-Revenue Multiple|Outset Medical Corp - Forward Price to Sales|ELMD (SmartVest) - Forward P/S Multiple|Market Cap to Future Revenue Ratio lensar.com LNSR|Price-to-Projected Revenue Ratio AVITA Medical (RCEL)|profoundmedical.com (PROF) - Projected Price to Revenue|Baird Medical - Forward Price-to-Revenue Multiple|Forward P/S Multiple EDAP TMS SA EDAP|Bovie Medical - Forward P/S Multiple|Market Cap to Expected Sales Ratio IceCure Medical Ltd ICCM|pulmonx.com (LUNG) - Price-to-Projected Revenue Ratio|Future Price to Revenue TELA (TELA Bio)|Price-to-Projected Revenue Ratio CytoSorbents Corp|Forward Price-to-Revenue Multiple Sensus (SRTS)|Forward P/S Multiple ZYXI|ECOR - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Vicarious Surgical RBOT|IINN: Market Cap to Projected Revenue|ICU: Forward Price-to-Revenue Multiple|IRIDEX Corporation - Price to Expected Revenue Ratio|INBS: Forward P/S Multiple|Projected Price to Revenue Beyond Air XAIR|Price-to-Projected Revenue Ratio Profusa|Price-to-Projected Revenue Ratio SSKN|Forward Price-to-Revenue Multiple NAOV (NanoVibronix)|Forward P/S Multiple Venus Concept Corporation (VERO)|Forward P/S Multiple NUWE (Nuwellis, Inc.)|AEMD - Forward Price-to-Revenue Multiple|ASXC - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Avinger Inc.|BSGM (BioSig Technologies, Inc) - Forward Price-to-Revenue Multiple|CUTR: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Know Labs, Inc.|NARI: Forward Price to Sales|Forward P/S Multiple NVRO|Forward P/S Multiple reshapelifesciences.com (RSLS)|Forward P/S Multiple SILK (Silk Road Medical Inc.)